HeartBeam, Inc. (NASDAQ:BEAT) Q4 2023 Earnings Call Transcript
HeartBeam, Inc. misses on earnings expectations. Reported EPS is $-0.15 EPS, expectations were $-0.12.
Biotelemetry Inc. (BEAT)
Market is closed
News
- 1 - 10
- Next >>
HeartBeam, Inc. (NASDAQ:BEAT) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to the HeartBeam Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.
HeartBeam, Inc. (NASDAQ:BEAT) Q2 2023 Earnings Call Transcript
Operator: Greetings and welcome to the HeartBeam Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
HeartBeam, Inc. (NASDAQ:BEAT) Q1 2023 Earnings Call Transcript
Operator: Greetings and welcome to the HeartBeam First Quarter 2023 Financial Results Conference Call. At this time all participants are in listen only mode.
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2022 Earnings Call Transcript
Operator: Greetings. And welcome to the HeartBeam Fourth Quarter and Full-Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Is BEAT A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Is BioTelemetry, Inc. (BEAT) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Selling BioTelemetry, Inc. (BEAT)
We hate to say this but, we told you so.
Should You Buy BioTelemetry, Inc. (BEAT)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Were Hedge Funds Right About Dumping BioTelemetry, Inc. (BEAT)?
A whopping number of 13F filings filed with U.S.
- 1 - 10
- Next >>
Billionaire Hedge Funds
